Numerous studies have reported persistent STAT activation in human cancers, including blood tumors and solid tumors such as leukemia, myeloma, lymphoma, melanoma, lung cancer, and prostate cancer [18], highlighting the potential of targeting STATs for anticancer therapy. This evidence concerns the gene SOAT1 and hematopoietic and lymphoid system neoplasm.